Atherosclerosis prevention and treatment in children and adolescents

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 4, 2010, Pages 513-528

  Oliveira, Fernanda Luisa Ceragioli ^a   Patin, Rose Vega ^a   Escrivão, Maria Arlete Meil Schimith ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adolescents; Atherosclerosis; Children; Diet; Drug; Dyslipidemia; Prevention; Risk factors; Therapy

Indexed keywords

AMINOTRANSFERASE; ANABOLIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BILE SALT; COLESEVELAM; COLESTYRAMINE; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN; ESTROGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METFORMIN; MEVINOLIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PRAVASTATIN; PROTEINASE INHIBITOR; RETINOIC ACID; ROSUVASTATIN; SIMVASTATIN; TESTOSTERONE;

ABDOMINAL DISCOMFORT; ADOLESCENCE; ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BEDTIME DOSAGE; BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHILDHOOD; CHOLELITHIASIS; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GASTROINTESTINAL SYMPTOM; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE INTOLERANCE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; METABOLIC SYNDROME X; MOTIVATION; MUSCLE DISEASE; MYALGIA; MYOPATHY; OBESITY; PATIENT EDUCATION; PHYSICAL ACTIVITY; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SKIN MANIFESTATION; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

ADOLESCENT; AGE FACTORS; ANIMALS; ATHEROSCLEROSIS; CHILD; DYSLIPIDEMIAS; HUMANS; LIFE STYLE; RISK FACTORS;

EID: 77951229159     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.170     Document Type: Review

References (143)

1. Berenson GS, Sririvan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and the early development of atherosclerosis. Bogalusa Heart Study. N. Engl. J. Med. 338(23), 1650-1666 (1998). (Pubitemid 28267909)
2. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 104(23), 2815-2819 (2001).
3. McMahan BW, Gidding SS, Malcom GT et al. Pathobiological determinants of atherosclerosis in young risk scores are associated with early and advanced atherosclerosis. Pediatrics 118, 1447-1455 (2006).
4. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) Study. Lancet 354, 1234-1241 (1999). (Pubitemid 29469351)
5. Koletzko B. Early nutrition and long-term healthy. In: Pediatric Nutrition in Practice. Koletzko B (Ed.). Karger, Basel, Switzerland, 67-70 (2008).
6. Ravelli ACJ, van der Meulen JHP, Osmond C, Barker DJP, Blecker OP. Infant feeding and adult glucose tolerance, lipid profile, blood pressure and obesity. Arch. Dis. Child. 82, 248-252 (2000). (Pubitemid 30305681)
7. Wong WW, Hachey DL, Insull W, Opekun AR, Klein PD. Effects of dietary cholesterol on cholesterol synthesis in breastfed and formula-fed infants. J. Lipid Res. 34, 1403-1411 (1993). (Pubitemid 23230317)
8. Bayley TM, Alaski M, Thorkelson T et al. Influence of formula versus breat milk on cholesterol syntesis rates. Pediatr. Res. 35, 135-140 (1994).
9. Bayley TM, Alaski M, Thorkelson T et al. Longer term effects of early dietary cholesterol level on synthesis and circulating cholesterol concentration in human infants. Metabolism 51, 25-33 (2002). (Pubitemid 34092433)
10. Owen CG, Whincup PJ, Odoki K, Gilg JA, Cook DG. Infant feeding and blood cholesterol: a study in adolescents and a systematic review. Pediatrics 110, 597-608 (2002). (Pubitemid 34976691)
11. Dremmers TA, Jones PJH, Wang Y, Krug S, Creutzinger V, Heubi JE. Effect of early cholesterol biosynthesis and plasma lipids among infants until 18 month's of age. Pediatrics 115, 1594-1601 (2005). (Pubitemid 43843168)
12. Newman WP, Freedam DS, Voors AW et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Study. N. Engl. J. Med. 314(3), 138-144 (1986).
13. McGill HC Jr, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effect of nonlipid risk factors on the atherosclerosis in young with favorable lipoprotein profile. Pathobiological Determinants of Atherosclerosis in Youth. Circulation 103(11), 1546-1550 (2002).
14. McGill HC Jr, McMahan CA, Malcom GT, Oalman MC, Strong JP. Effects of serum lipoproteins and smoking on the atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler. Thromb. Vasc. Biol. 17(1), 95-106 (1997). (Pubitemid 27057330)
15. Magnussen CG, Venn A, Thomson R et al. The association of pediatric low and high density lipoprotein cholesterol dyslipidemia classification and change in dyslipidemia status with carotid intima-media thickness in adulthood. J. Am. Coll. Cardiol. 53(10), 860-869 (2009).
16. Gidding SS, Lichtenstein AH, Faith MS et al. Implementing American Heart Association Pediatric and Adult Nutrition Guidelines. A scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 119, 1161-1175 (2009).
17. Daniels SR, Greer FR; the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 122, 198-208 (2008).
18. Lichtenstein AH, Appel LJ, Brands M et al. Diet and lifestyle recommendations revision 2006. A scientific statement from the American Heart Association Nutrition Committee. Circulation 114(1), 82-96 (2006). (Pubitemid 44305278)
19. Capps O, Cleveland L, Park J. Dietary behaviors associated with total fat and saturated fat intake. J. Am. Diet. Assoc. 102, 490-496, 501-502 (2002). (Pubitemid 40434208)
20. Han SN, Leka LS, Lichtensteins AH, Ausman LM, Schaerfer EJ, Meydani N. Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J. Lipid Res. 43, 445-452 (2002).
21. He FJ, Marrero NM, MacGregor GA. Salt intake is related to soft drink consumption in children and adolescents. A link to obesity? Hypertension 51, 629-634 (2008).
22. Hill AM, Fleming JA, Kris-Etherton PM. The role of diet and nutritional supplements in preventing and treating cardivascular disease. Curr. Opin. Cardiol. 433-441 (2009).
23. Holt EM, Steffen LM, Moran A et al. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. J. Am. Diet. Assoc. 109, 414-421 (2009).
24. Mensink RP, Kantan MB. Trans monounsaturated fatty acids in nutrition and their impact on serum lipoprotein levels in man. Prog. Lipid Res. 32, 111-122 (1993).
25. Kris-Etherton PM, Griel AE, Psota TL, Gebauer SK, Zhang J, Etherton TD. Dietary stearic acid and risk of caridovascular disease: intake, sources, digestion, and absorption. Lipids 40(12), 1193-1200 (2005).
26. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N. Engl. J. Med. 340(25), 1933-1939 (1999).
27. Thijssen MAMA, Hornstra G, Mensink R. Stearic, oleic and linoleic acids have comparable effects on markers of thrombotic tendency in healthy human subjects. J. Nutr. 135, 2805-2811 (2005). (Pubitemid 43156545)
28. Simopoulos AP. The Mediterranean diets: what is so special about the diet of Greece? The scientific evidence. J. Nutr. 131(11 Suppl.), 3065S-3073S (2001).
29. Wang C, Harris WS, Chung M et al. n-3 fatty acids from fish or fish-oil supplements, but not (a)linolenic acid, benefit cardiovascular disease outcomes in primary and secondary prevention studies: a systematic review. Am. J. Clin. Nutr. 84, 5-17 (2006). (Pubitemid 44699166)
30. Breslow JL. n-3 fatty acids and cardiovascular disease. Am. J. Clin. Nutr. 83(Suppl.), 1477S-1482S (2006). (Pubitemid 44713088)
31. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr. Opin. Nutr. Metab. Care 10, 129-135 (2007). (Pubitemid 46220303)
32. Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. J. Am. Diet. Assoc. 109(4), 668-679 (2009).
33. Introduction to pediatric atherosclerosis prevention. In: Pediatric Atherosclerosis prevention. Identification and treatment of the children with high cholesterol. Jacobson MS (Ed.). Harwood Academic Publishers, Chur, Switzerland (1991).
34. Woollett LA, Dietschy JM. Effect of long-chain fatty acids on low-density-lipoprotein-cholesterol metabolism. Am. J. Clin. Nutr. 60(6 Suppl.), 991S-996S (1994). (Pubitemid 24371834)
35. Kris-Etherton PM. AHA Science Advisory. Monounsaturated fatty acids and risk of cardiovascular disease. American Heart Association. Nutrition Committee. Circulation 100(11), 1253-1258 (1999).
36. Patch CS, Tapsell LC, Williams PG, Gordon M. Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. Vasc. Health Risk Manag. 2(2), 157-162 (2006). (Pubitemid 43853430)
37. Iughetti L, Predieri B, Bruzzi P, Balli F. Approaches to dyslipidemia treatment in children and adolescents. Expert Rev. Endocrinol. Metab. 3(5), 615-633 (2008).
38. Clifton P, Colquhoun D, Hewat C. Dietary intervention to lower serum cholesterol. Australian Fam. Physic. 38(6), 424-428 (2009).
39. Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Am. J. Clin. Nutr. 69(3), 403-410 (1999).
40. Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr. Res. DOI: 10.3402/fnr.v52i0.1811 (2008).
41. Hallikainen M, Sarkkinen E, Wester I, Uusitupa M. Short-term LDL cholesterol-lowering efficacy of plant stanol esters. BMC Cardiovasc. Disord. 2, 14 (2002). (Pubitemid 38824796)
42. Clifton PM, Noakes M, Sullivan D et al. Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread and cereal. Eur J. Clin. Nutr. 58(3), 503-509 (2004). (Pubitemid 38443712)
43. Gylling H, Puska P, Vartiainen E, Miettinen TA. Retinol, vitamin D, carotenes and a-tocopherol in serum of a moderately hypercholesterolemic population consuming sitostanol ester margarine. Atherosclerosis 145(2), 279-285 (1999). (Pubitemid 29359135)
44. Kavey REW, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science, the Councils on Cardiovascular Disease in Young, Epidemioloy and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease, and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the Americam Academy of Pediatrics. Circulation 114, 2710-2738 (2006).
45. Dauchet L, Amouyel P, Dallongeville J, Medscape. Fruits, vegetables and coronary heart disease. Nat. Rev. Cardiol. Advance 6(9), 599-608 (2009).
46. Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL. Concentrated oat b-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr. J. 6, 6 (2006). (Pubitemid 46548451)
47. Theuwissen E, Mensink RP. Simultaneous intake of b-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. J. Nutr. 137, 583-588 (2007). (Pubitemid 46397487)
48. Said Butt M, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS. Oat: unique among the cereals. Eur. J. Clin. Nutr. 47(2), 67-79 (2008).
49. Maki KC, Shinnick F, Seeley MA et al. Food products containing free tall oil-based phytosterols and oat b-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. J. Nutr. 133(3), 808-813 (2003). (Pubitemid 36268359)
50. Williamson G, Holst B. Dietary reference intake (DRI) value for dietary polyphenols: are we heading in the right direction? Br. J. Nutr. 99, S55-S58 (2008). (Pubitemid 351936566)
51. Lampe JW, Atkinson C, Hullar MSJ. Assessing exposure to lignans and their metabolites in humans. J. AOAC Intern. 89(4), 1174-1181 (2006). (Pubitemid 44972069)
52. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99, 1355-1362 (1999). (Pubitemid 29129922)
53. Muir AD. Flax lignans-analytical methods and how they influence our understanding of biological activity. J. AOAC Intern. 89(4), 1147-1157 (2006).
54. Pan A, Yu D, Demark-Wahnefried W, Franco OH, Lin X. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am. J. Clin. Nutr. 90(2), 288-297 (2009).
55. Vita J. Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am. J. Clin. Nutr. 81(1), 292S-297S (2005).
56. Williams JK, Clarkson TB. Dietary soy isoflavones inhibit in-vivo constrictor responses of coronary arteries to collagen-induced platelet activation. Coron. Artery Dis. 9, 759-764 (1998).
57. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health. Circulation 113, 1034-1044 (2006).
58. Matthan NR, Jalbert SM, Ausman LM, Kuvin JT, Karas RH, Lichtenstein AH. Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects. Am. J. Clin. Nutr. 85(4), 960-966 (2007).
59. Hamed MS, Gambert S, Bliden KP et al. Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. South Med. J. 101(12), 1203-1208 (2008).
60. Murphy KJ, Chronopoulos AK, Singh I et al. Dietary flavanols and procyanidin oligomers from cocoa (Theobroma cacao) inhibit platelet function. Am. J. Clin. Nutr. 77(6), 1466-1473 (2003). (Pubitemid 39655281)
61. Erlund I, Koli R, Alftan G et al. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. Am. J. Clin. Nutr. 87, 323-331 (2008). (Pubitemid 351226067)
62. Pignatelli P, Pulcinelli FM, Celestini A et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagoning the intracellular production of hydrogen peroxide. Am. J. Clin. Nutr. 72, 1150-1155 (2000).
63. Freedman JE, Parker C, Li L et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 103, 2792-2798 (2001). (Pubitemid 32550066)
64. Castilla P, Echarri R, Dávalos A et al. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am. J. Clin. Nutr. 84, 252-262 (2006). (Pubitemid 44699192)
65. Blomhoff R. Dietary antioxidants and cardiovascular disease. Curr. Opin. Lipidol. 16(1), 47-54 (2005). (Pubitemid 40333366)
66. Riccioni G, Bucciarelli T, Mancini B et al. Antioxidant vitamin supplementation in cardiovascular diseases. An. Clin. Lab. Sci. 37, 89-95 (2007). (Pubitemid 46311004)
67. Jacob K, Periago MJ, Böhm V, Berruezo GR. Influence of lycopene and vitamin C from tomato juice on boimarkers of oxidative stress and inflammation. Br. J. Nutr. 99, 137-146 (2008). (Pubitemid 350286147)
68. Daniels SR. Exercise and lipid abnormalities. Pediatr. Cardiol. 20, 71-77 (1999).
69. Katzmarzyk PT, Malina RM, Bouchard C. Physical activity, physical fitness, and coronary heart disease risk facyors in youth: the Quebec Family Study. Prev. Med. 29, 555-562 (1999). (Pubitemid 30026551)
70. Tolfrey K, Jones AM, Campbell IG. The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents. Sports Med. 29, 99-112 (2000). (Pubitemid 30110382)
71. Janz KF, Dawson JD, Mahoney LT. Increases in physical fitness during childhood improve cardiovascular health during adolescence: the Muscatine Study. Int. J. Sports Med. 23(Suppl. 1), S15-S21 (2002).
72. Kavey REW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107, 1562-1566 (2003). (Pubitemid 36378499)
73. Giuliano IC, Caramelli B, Pellanda L, Duncan B, Mattos S, Fonseca FH. I Guideline for preventing atherosclerosis in childhood and adolescence. Int. J. Atheroscler. 1(1), 1-30 (2006).
74. Irace C, Scavelli F, Carallo C, Serra R, Cortese C, Gnasso A. Body mass index, metabolic syndrome and carotid atherosclerosis. Coronary Artery Disease 20, 94-99 (2009).
75. Shalitin S, Phillip M. Frequency of cardiovascular risk factors in obese children and adolescents referred to a tertiary care center in Israel. Horm. Res. 69, 152-159 (2008). (Pubitemid 351161043)
76. Sun SS, Liang R, Huang TTK et al. Childhood obesity predicts adult metabolic syndrome: the Fels Longitudinal Study. J. Pediatr. 152, 191-200 (2008).
77. Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in childhood predicts adult metabolic syndrome and Type 2 diabetes mellitus 25 to 30 years later. J. Pediatr. 152, 201-206 (2008).
78. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight tocardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 103(Pt 1), 1175-1182 (1999).
79. Steinberger J, Moran A, Hong CP, Jacobs DR Jr, Sinaiko AR. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J. Pediatr. 138, 469-473 (2001). (Pubitemid 32319717)
80. Sinaiko AR, Jacobs DR Jr, Steinberger J et al. Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness andother risk factors. J. Pediatr. 139, 700-707 (2002). (Pubitemid 33097437)
81. Zhang CX, Tse LA, Deng XQ, Jiang ZQ. Cardiovascular risk factors in overweight and obese Chinese children. A comparison of weight-for-height index and BMI as the screening criterion. Eur. J. Nutr. 47, 244-250 (2008).
82. Jiang X, Srinivasan SR, Bao W, Berenson GS. Association of fasting insulin with blood pressure in young individuals: the Bogalusa Heart Study. Arch. Intern. Med. 153, 323-328 (1993). (Pubitemid 23058977)
83. Rocchini AP, Key J, Bondie D et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N. Engl. J. Med. 321, 580-585 (1989). (Pubitemid 19212870)
84. Su HY, Sheu WH, Chin HM, Jeng CY, Chen YD, Reaven GM. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am. J. Hypertens. 8, 1067-1071 (1995).
85. Rocchini AP, Moorehead C, Katch V, Key J, Finta KM. Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 19(Pt 2), 615-620 (1992).
86. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood. A systematic review and meta-regression analysis. Circulation 117, 3171-3180 (2008). (Pubitemid 351301515)
87. Kavey REW, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients: a Scientific Statement from the American Heart Association Expert Panel on Population and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114, 2710-2738 (2006). (Pubitemid 46015982)
88. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 114(2), 555-576 (2004). (Pubitemid 39006657)
89. Mc Crindle BW. Hyperlipidemia in children. Thrombosis Res. 118, 49-68 (2006).
90. Alwaili K, Alrasadi K, Awan Z, Genest J. Approach to the diagnosis and management of lipoprotein disorders. Curr. Opin. Endocrinol. Diabetes Obes. 16, 132-140 (2009).
91. Wiegman A, Rodenburg J, de Jongh S et al. Family history and cardiovascular history in familial hypercholesterolemia. Data in more than 1000 children. Circulation 1107, 1473-1478 (2003). (Pubitemid 36378483)
92. Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial combined hyperlipidemia in childhood. J. Pediatr. 116, 514-524 (1990).
93. Brinton EA Lipid abnormalities in the metabolic syndrome. Curr. Diabetes Rep. 3, 65-72 (2003).
94. Vinik AI. The metabolic basis of atherogenic dyslipidemia. Clinical Cornerstone 7(2/3), 27-35 (2005).
95. Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab. Syndr. Relat. Disord. 7(2), 83-88 (2009).
96. Cook S, Weitzman M, Auirnger P Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: finding from the Third National Health and Nutrition Examination Survey 1988-1994. Arch. Pediatr. Adolesc. Med. 157, 821-827 (2003). (Pubitemid 36988016)
97. Janssen I, Katzmarzyk PT, Srinivasan SR et al. Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics 115, 1623-1630 (2005). (Pubitemid 43843172)
98. Farley J, Gona P, Crain M et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J. Acquir. Immune Defic. Syndr. 38, 480-487 (2005). (Pubitemid 40381558)
99. Cheseaux JJ, Jotterand V, Aebi C et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J. Acquir. Immune Defic. Syndr. 30, 288-293 (2002). (Pubitemid 34774076)
100. Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J. Acquir. Immune Defic. Syndr. 47, 607-614 (2008). (Pubitemid 351442017)
101. Giuliano ICB, Freitas SFT, Souza M, Caramelli B. Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. Coron. Art. Dis. 19, 167-172 (2008). (Pubitemid 351555970)
102. American Academy of Pediatrics. National Cholesterol Education Program (NCEP): Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89, 525-584 (1992).
103. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. J. Clin. Endocrinol. Metab. 93(11), 4200-4209 (2008). (Pubitemid 352789511)
104. McGill HC, Mc Mahan CA, Zieske AW et al. Associations of coronary heart disease risk factors wirh the intermediate lesion of atherosclerosis in young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY). Arterioscler. Thromb. Vasc. Biol. 20(1), 1998-2004 (2000).
105. Mudd JO, Borlaug BA, Johnston PV et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J. Am. Coll. Cardiol. 50, 1735-1741 (2007).
106. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apoprotein B and AI distribution in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin. Chem. 43, 2364-2378 (1997). (Pubitemid 28022974)
107. Srinivasan SR, Myers L, Berenson GS. Distribuition and correlates of non-high-density cholesterol in children: the Bogalusa Heart Study. Pediatrics 110, E29 (2002).
108. Liacouras CA, Shamir R. Pediatric cholesterol screening: missed opportunnities. Isr. J. Med. Sci. 33, 659-662 (1997). (Pubitemid 27499704)
109. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipids disordess in children and adolescens: a Systematic evidence review for the US Preventine Task Force. Pediatrics 120, E189-E214 (2007). (Pubitemid 47036251)
110. Liu CS, Lin CC, Shih HC, Li TC. The advisability of implemmenting cholesterol screening in school-age children and adolescent with a family history of cardiovascular disease and hyperlipidemia. Fam. Pract. 16, 501-505 (1999).
111. Derinoz O, Tumer L, Hasanoglu A, Pasaoglu H, Aksakal FN, Ceyhan MN. Cholesterol screening in school children: is family history reliable to choose the ones to screen? Acta Pediatr. 96, 1794-1798 (2007). (Pubitemid 350132039)
112. De Castro PS, Oliveira FL. Prevention of atherosclerosis and drug treatment of high-risk lipid abnormalities in children and adolescents. J. Pediatr. (Rio J.) 85(1), 6-14 (2009).
113. Zappalla FR, Gidding SS. Lipid management in children. Endocrinol. Metab. Clin. N. Am. 38, 171-183 (2009).
114. Spear BA, Barlow SE, Ervin C et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics 120(Suppl. 4), S254-S288 (2007).
115. Mark AE, Janssen I. Dose-response relation between physical activity and blood pressure in youth. Med. Sci. Sports Exerc. 40(6), 1007-1012 (2008).
116. Maron BJ, Chaitman BR, Ackerman MJ et al. Recommendation for physical activity and recreational sports participation for young patients with genetic cardiovascular disease. Circulation 109(22), 2807-2816 (2004).
117. Sääkslahti A, Numminen P, Varstala V et al. Physical activity as a preventive measure for coronary heart disease risk factors in early childhood. Scand. J. Med. Sci. Sports 14, 143-149 (2004). (Pubitemid 38758932)
118. Strong WB, Malina RM, Blinkie CJ et al. Evidence-based physical activity for school-age youth. J. Pediatr. 146(6), 732-737 (2005). (Pubitemid 40840591)
119. McCrindle BW, Urbina EM, Dennison BA et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. Circulation 115, 1948-1967 (2007). (Pubitemid 46598908)
120. Kelley A, Kelley KS. Aerobic exercise and lipids and lipoproteins in children and adolescents: a meta-analysis of randomized controlled trials. Atherosclerosis 191, 447-453 (2007). (Pubitemid 46400707)
121. Avis HJ, Vissers MN, Stein EA et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 27, 1803-1810 (2007). (Pubitemid 47207177)
122. Daniels SR. Use of pharmacologic agents for treatment of diabetes mellitus, dyslipidemia, and hypertension in children and adolescents. Arch Pediatr. Adolesc. Med. 163 (4), 389-391 (2009).
123. Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur. J. Pediatr. 162, 421-425 (2003). (Pubitemid 36693745)
124. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J. Pediatr. 143, 74-80 (2003). (Pubitemid 36928572)
125. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur. J. Pediatr. 162, 421-425 (2003). (Pubitemid 36693745)
126. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292, 331-337 (2004). (Pubitemid 38944256)
127. Hedman M, Matikainen T, Föhr A et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J. Clin. Endocrinol. Metab. 90, 1942-1952 (2005). (Pubitemid 40586225)
128. Clauss SB, Holmes KW, Hopkins P et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 116, 682-688 (2005). (Pubitemid 44336686)
129. Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116, 664-668 (2007). (Pubitemid 47356351)
130. Kay JP, Alemzadeh R, Langley G et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50, 1457-1461 (2001). (Pubitemid 34007417)
131. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance with fasting hyperinsulinemia and family history of Type 2 diabetes. Pediatrics 107, 1-7 (2001).
132. Ascaso J, Gonzalez Santos P, Hernandez Mijares A et al. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Am. J. Cardiovasc. Drugs 7(1), 39-58 (2007). (Pubitemid 46698514)
133. McGill HC, McMahan CA, Gidding SS. Preventing heart disease in the 21st Century: implications of the pathological determinants of atherosclerosis in young (PDAY) study. Circulation 117(9), 1216-1227 (2008).
134. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur. J. Cardiovasc. Prev. Rehabil. 16(1), 1-9 (2009).
135. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics 119, 370-380 (2007). (Pubitemid 46397763)
136. Dubé MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37, 613-627 (2003).
137. Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol. 94, 882-888 (2004). (Pubitemid 39349552)
138. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160 (2003). (Pubitemid 36835963)
139. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E, He FH. Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 92, 1287-1293 (2003). (Pubitemid 37431136)
140. Coletti RB, Neufeld EJ, Bruckert et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 92, 78-82 (1993).
141. Hayman LL, Meininger JC, Daniels SR et al. Primary prevention of cardiovascular disease in nursing practice: focus on children and youth: a scientific statement from the American Heart Association Committee on Atherosclerosis, Hypertension, and Obesity in Youth of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity, and Metabolism. Circulation 116, 334-357 (2007).
142. Bays HE, Neff D, Tomassini JE, Terhakovec AM. Ezetimibe: cholesterol lowering and beyond. Exp. Rev. Cardiovasc. Ther. 6(4), 447-470 (2008).
143. Knop RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 24, 729-741 (2003). . (Pubitemid 36458985)